Hyperthyroidism is a condition where the thyroid gland produces an excess of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3). This overproduction accelerates the body’s metabolism and can cause a variety of symptoms.
The condition can arise from several causes, such as Graves’ disease (an autoimmune disorder), toxic adenomas, or thyroiditis (inflammation of the thyroid). Hyperthyroidism affects individuals of all ages but is more common in:
- Women
- Adults aged 20 to 40
- Patients with other autoimmune conditions
- Family history of thyroid problems
Hyperthyroidism can also be a side effect of immune checkpoint inhibitor therapy such as:
PD-1 inhibitors:
- Pembrolizumab (Keytruda®)
- Nivolumab (Opdivo®)
- Cemiplimab (Libtayo®)
- Dostarlimab (Jemperli®)
- Retifanlimab (Zynyz®)
- Toripalimab (Loqtorzi®)
PD-L1 inhibitors:
- Atezolizumab (Tecentriq®)
- Durvalumab (Imfinzi®)
- Avelumab (Bavencio®)
CTLA-4 inhibitors:
- Ipilimumab (Yervoy®)
- Tremelimumab (Imjudo®)